Figure 6

3PO suppresses the increase in epidermal thickness and CD3⁺T cell infiltration caused by imiquimod. BALB/c mice were administered a daily topical dose of 62.5 mg of imiquimod cream (5%) over a shaved area on the back for 5 days and thirty minutes following each daily administration of imiquimod, the mice were injected intraperitoneally with either DMSO or 3PO 0.07 mg/gm daily. (A) After 5 daily topical applications of imiquimod with intraperitoneal administration of DMSO or 3PO, the exposed skin was resected, fixed in formalin, embedded in paraffin, sectioned and stained with hematoxylin and eosin. (B) After 5 daily topical applications of imiquimod with intraperitoneal administration of DMSO or 3PO, the exposed skin was resected, fixed in formalin, embedded in paraffin, sectioned and CD3⁺ T cells were detected by immunohistochemistry. Data are representative of three independent experiments.